Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma
Immunosuppression, both iatrogenic and disease‐related, is associated with a greatly increased incidence of cutaneous SCC (cSCC) and with aggressive cSCC and worse disease outcomes. Consequently, rapid access to skin cancer services and prudent surgical choices, such as circumferential margin assess...
Saved in:
Published in | Journal of the European Academy of Dermatology and Venereology Vol. 33; no. S8; pp. 57 - 60 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.12.2019
|
Online Access | Get full text |
Cover
Loading…
Abstract | Immunosuppression, both iatrogenic and disease‐related, is associated with a greatly increased incidence of cutaneous SCC (cSCC) and with aggressive cSCC and worse disease outcomes. Consequently, rapid access to skin cancer services and prudent surgical choices, such as circumferential margin assessment, is essential when treating advanced cSCC in an immunosuppressed patient. For high‐risk cancers and control of cSCC multiplicity, additional strategies should be actively considered within the multidisciplinary clinical care team. These include minimization or revision of immunosuppressive medications, systemic chemoprevention (including retinoids, nicotinamide, capecitabine) and adjuvant therapies such as radiotherapy. Unfortunately, there is a relative paucity of good evidence for many of these treatments in the immunosuppressed. Systemic treatments for metastatic cSCC are often contraindicated in organ transplant recipients, notably checkpoint inhibitor immunotherapy. There are also toxicity concerns with some conventional chemotherapies and EGFR inhibitors. Until recently, clinical trials have largely excluded immunosuppressed individuals. Development of more effective treatment for advanced cSCC in this high‐risk group and prospective clinical trials are now research priorities. |
---|---|
AbstractList | Immunosuppression, both iatrogenic and disease‐related, is associated with a greatly increased incidence of cutaneous SCC (cSCC) and with aggressive cSCC and worse disease outcomes. Consequently, rapid access to skin cancer services and prudent surgical choices, such as circumferential margin assessment, is essential when treating advanced cSCC in an immunosuppressed patient. For high‐risk cancers and control of cSCC multiplicity, additional strategies should be actively considered within the multidisciplinary clinical care team. These include minimization or revision of immunosuppressive medications, systemic chemoprevention (including retinoids, nicotinamide, capecitabine) and adjuvant therapies such as radiotherapy. Unfortunately, there is a relative paucity of good evidence for many of these treatments in the immunosuppressed. Systemic treatments for metastatic cSCC are often contraindicated in organ transplant recipients, notably checkpoint inhibitor immunotherapy. There are also toxicity concerns with some conventional chemotherapies and EGFR inhibitors. Until recently, clinical trials have largely excluded immunosuppressed individuals. Development of more effective treatment for advanced cSCC in this high‐risk group and prospective clinical trials are now research priorities. Abstract Immunosuppression, both iatrogenic and disease‐related, is associated with a greatly increased incidence of cutaneous SCC ( cSCC ) and with aggressive cSCC and worse disease outcomes. Consequently, rapid access to skin cancer services and prudent surgical choices, such as circumferential margin assessment, is essential when treating advanced cSCC in an immunosuppressed patient. For high‐risk cancers and control of cSCC multiplicity, additional strategies should be actively considered within the multidisciplinary clinical care team. These include minimization or revision of immunosuppressive medications, systemic chemoprevention (including retinoids, nicotinamide, capecitabine) and adjuvant therapies such as radiotherapy. Unfortunately, there is a relative paucity of good evidence for many of these treatments in the immunosuppressed. Systemic treatments for metastatic cSCC are often contraindicated in organ transplant recipients, notably checkpoint inhibitor immunotherapy. There are also toxicity concerns with some conventional chemotherapies and EGFR inhibitors. Until recently, clinical trials have largely excluded immunosuppressed individuals. Development of more effective treatment for advanced cSCC in this high‐risk group and prospective clinical trials are now research priorities. |
Author | Proby, C.M. Willenbrink, T.J. Seckin, D. Harwood, C.A. Jambusaria‐Pahlajani, A. Arron, S. |
Author_xml | – sequence: 1 givenname: T.J. surname: Willenbrink fullname: Willenbrink, T.J. organization: The University of Texas at Austin‐Dell Medical School – sequence: 2 givenname: A. surname: Jambusaria‐Pahlajani fullname: Jambusaria‐Pahlajani, A. organization: The University of Texas at Austin‐Dell Medical School – sequence: 3 givenname: S. surname: Arron fullname: Arron, S. organization: University of California – sequence: 4 givenname: D. surname: Seckin fullname: Seckin, D. organization: Baskent University – sequence: 5 givenname: C.A. surname: Harwood fullname: Harwood, C.A. organization: Queen Mary University of London – sequence: 6 givenname: C.M. orcidid: 0000-0002-3292-4836 surname: Proby fullname: Proby, C.M. email: c.proby@dundee.ac.uk organization: Ninewells Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31833603$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kMtOwzAQRS0Eog9Y8APIS1iktePEsZeovFWJTWFrOc5ETZU4bZy06t_jkMKO2cxodObqzp2gc1tbQOiGkhn1Nd9k-xmNRcTO0JhGXASMCHaOxkSGPJAyliM0cW5DCKEeu0QjRgVjnLAx0qsGdFuBbbHebptamzU4XFhcVFVna9f5JTgHGd7qtvCYw4eiXWOd7bU1fm26VluoO4fdrtNVPxgoS2x0YwpbV_oKXeS6dHB96lP0-fy0WrwGy4-Xt8XDMjC9k4AzQ3hiTMRZlAKkaZxISbngcSh0QkISgWQkyyTj_gCYSZKcZILnidQmTzibortB13-x68C1qipcb2Wwp0LGIi5FzBKP3g-oaWrnGsjVtikq3RwVJapPVPlE1U-inr09yXZpBdkf-RuhB-YDcChKOP6vpN4fvwbJb_PhgzQ |
CitedBy_id | crossref_primary_10_3390_ijms22073567 crossref_primary_10_1016_j_pathol_2023_07_003 crossref_primary_10_1146_annurev_pathol_042320_120056 crossref_primary_10_3389_fmed_2024_1381492 crossref_primary_10_1136_jitc_2022_005082 crossref_primary_10_1245_s10434_022_11669_z crossref_primary_10_2147_CMAR_S265775 crossref_primary_10_1007_s00403_024_03109_7 crossref_primary_10_2217_fon_2023_0389 crossref_primary_10_1016_j_ejca_2023_113252 crossref_primary_10_1080_14737140_2021_1876567 |
Cites_doi | 10.1111/dsu.12049 10.1200/JCO.2012.45.6376 10.1056/NEJMc1509268 10.1016/j.jaad.2012.06.009 10.1001/jamadermatol.2018.4219 10.1016/j.jaad.2017.08.058 10.1056/NEJMoa1506197 10.1016/j.ctrv.2017.12.004 10.1016/j.jaad.2015.02.1131 10.1200/JCO.2017.76.6691 10.1097/TP.0000000000001644 10.3390/jcm4061229 10.1001/jamadermatol.2016.0192 10.1007/s11864-012-0195-3 10.1126/science.1114233 10.1111/ajt.14238 10.1111/ajt.15071 10.1097/01.MLG.0000158349.64337.ED 10.1001/archderm.139.3.301 10.1111/bjd.14662 10.1001/archderm.141.4.456 10.1002/cncr.30601 10.1016/j.jaad.2010.11.063 10.1016/j.healun.2007.09.019 10.1111/j.1524-4725.2007.34040.x 10.1001/jamadermatol.2015.4994 10.1016/j.jaad.2005.08.055 10.1634/theoncologist.2018-0195 10.1097/DSS.0000000000001645 10.1056/NEJMoa1204166 |
ContentType | Journal Article |
Copyright | 2019 European Academy of Dermatology and Venereology 2019 European Academy of Dermatology and Venereology. |
Copyright_xml | – notice: 2019 European Academy of Dermatology and Venereology – notice: 2019 European Academy of Dermatology and Venereology. |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1111/jdv.15843 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-3083 |
EndPage | 60 |
ExternalDocumentID | 10_1111_jdv_15843 31833603 JDV15843 |
Genre | reviewArticle Journal Article Review |
GroupedDBID | --- --K .3N .GA .Y3 05W 0R~ 10A 1B1 1OB 1OC 1~5 29L 31~ 33P 36B 3SF 4.4 4G. 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANLZ AAONW AAQFI AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADMUD ADOZA ADZMN AE3 AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFTJW AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG CO8 COF CS3 CYRXZ D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD ESX EX3 F00 F01 F04 F5P FDB FEDTE FGOYB FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 NF~ NQ- O66 O9- OIG OVD OZT P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K R2- RIG RIWAO RJQFR ROL RPZ RX1 SAMSI SEW SUPJJ TEORI UB1 UHS W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c3603-63c067cc4634beebb57991686528a70204e930dd936c36e3c77f0d86f79acf763 |
IEDL.DBID | DR2 |
ISSN | 0926-9959 |
IngestDate | Sat Aug 17 01:50:37 EDT 2024 Fri Aug 23 04:09:27 EDT 2024 Sat Sep 28 08:32:37 EDT 2024 Sat Aug 24 01:09:31 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | S8 |
Language | English |
License | 2019 European Academy of Dermatology and Venereology. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3603-63c067cc4634beebb57991686528a70204e930dd936c36e3c77f0d86f79acf763 |
Notes | Funding Source None. Conflict of interest ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ORCID | 0000-0002-3292-4836 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.15843 |
PMID | 31833603 |
PQID | 2334698537 |
PQPubID | 23479 |
PageCount | 4 |
ParticipantIDs | proquest_miscellaneous_2334698537 crossref_primary_10_1111_jdv_15843 pubmed_primary_31833603 wiley_primary_10_1111_jdv_15843_JDV15843 |
PublicationCentury | 2000 |
PublicationDate | December 2019 2019-Dec 2019-12-00 20191201 |
PublicationDateYYYYMMDD | 2019-12-01 |
PublicationDate_xml | – month: 12 year: 2019 text: December 2019 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of the European Academy of Dermatology and Venereology |
PublicationTitleAlternate | J Eur Acad Dermatol Venereol |
PublicationYear | 2019 |
References | 2015; 1 2003; 139 2015; 4 2015; 73 2005; 115 2016; 75 2008; 34 2018; 63 2012; 367 2012; 13 2018; 18 2005; 141 2013; 39 2017; 17 2019; 24 2019; 45 2013; 31 2015; 373 2005; 53 2016; 374 2011; 65 2005; 309 2018; 78 2017; 123 2017; 101 2012; 67 2019; 155 2016; 152 2018; 36 2007; 26 e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 Breithaupt AD (e_1_2_9_24_1) 2015; 1 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 e_1_2_9_29_1 |
References_xml | – volume: 17 start-page: 1974 year: 2017 end-page: 1991 article-title: Chemotherapy and transplantation: the role of immunosuppression in malignancy and a review of antineoplastic agents in solid organ transplant recipients publication-title: Am J Transplant – volume: 39 start-page: 634 year: 2013 end-page: 645 article-title: Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients publication-title: Dermatol Surg – volume: 123 start-page: 2054 year: 2017 end-page: 2060 article-title: A multi‐institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck publication-title: Cancer – volume: 63 start-page: 116 year: 2018 end-page: 121 article-title: Cancer immunotherapy in a neglected population: The current use and future of T‐cell‐mediated checkpoint inhibitors in organ transplant patients publication-title: Cancer Treat Rev – volume: 4 start-page: 1229 year: 2015 end-page: 1239 article-title: Cutaneous squamous cell carcinomas in organ transplant recipients publication-title: J Clin Med – volume: 36 start-page: 2612 year: 2018 end-page: 2620 article-title: Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5‐year results publication-title: J Clin Oncol – volume: 374 start-page: 896 year: 2016 end-page: 898 article-title: Tumor regression and allograft rejection after administration of anti‐PD‐1 publication-title: N Engl J Med – volume: 24 start-page: 394 year: 2019 end-page: 401 article-title: Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue publication-title: Oncologist – volume: 101 start-page: e133 year: 2017 end-page: e141 article-title: Risk of aggressive skin cancers after kidney retransplantation in patients with previous posttransplant cutaneous squamous cell carcinomas: A retrospective study of 53 cases publication-title: Transplantation – volume: 75 start-page: 1073 year: 2016 end-page: 1075 article-title: A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients publication-title: Br J Dermatol – volume: 13 start-page: 354 year: 2012 end-page: 376 article-title: Management of non‐melanoma skin cancer in immunocompromised solid organ transplant recipients publication-title: Curr Treat Options Oncol – volume: 31 start-page: 1317 year: 2013 end-page: 1323 article-title: Two‐year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus publication-title: J Clin Oncol – volume: 115 start-page: 870 year: 2005 end-page: 875 article-title: Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: Combined treatment should be considered best practice publication-title: Laryngoscope – volume: 65 start-page: 263 year: 2011 end-page: 279 article-title: Skin cancer in solid organ transplant recipients: advances in therapy and management, part II: management of skin cancer in solid organ transplant recipients publication-title: J Am Acad Dermatol – volume: 78 start-page: 249 year: 2018 end-page: 261 article-title: Cutaneous squamous cell carcinoma: Management of advanced and high‐stage tumors publication-title: J Am Acad Dermatol – volume: 34 start-page: 216 year: 2008 end-page: 223 article-title: The effects of sirolimus on wound healing in dermatologic surgery publication-title: Dermatol Surg – volume: 26 start-page: 1340 year: 2007 end-page: 1344 article-title: Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab publication-title: J Heart Lung Transplant – volume: 152 start-page: 683 year: 2016 end-page: 690 article-title: Nonmelanoma skin cancer with aggressive subclinical extension in immunosuppressed patients publication-title: JAMA Dermatol – volume: 45 start-page: 52 year: 2019 end-page: 57 article-title: Association of postoperative antibiotics with surgical site infection in Mohs micrographic surgery publication-title: Dermatol Surg – volume: 309 start-page: 1871 year: 2005 end-page: 1874 article-title: Azathioprine and UVA light generate mutagenic oxidative DNA damage publication-title: Science – volume: 73 start-page: 120 year: 2015 end-page: 126 article-title: Squamous cell carcinoma with aggressive subclinical extension: 5‐year retrospective review of diagnostic predictors publication-title: J Am Acad Dermatol – volume: 139 start-page: 301 year: 2003 end-page: 306 article-title: Defining the clinical course of metastatic skin cancer in organ transplant recipients. A multicentre collaborative study publication-title: Arch Dermatol – volume: 18 start-page: 3065 year: 2018 end-page: 3071 article-title: Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients publication-title: Am J Transplant – volume: 155 start-page: 298 year: 2019 end-page: 306 article-title: Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England publication-title: JAMA Dermatol – volume: 152 start-page: 419 year: 2016 end-page: 428 article-title: Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease‐specific death: a systematic review and meta‐analysis publication-title: JAMA Dermatol – volume: 373 start-page: 1618 year: 2015 end-page: 1626 article-title: A phase 3 randomized trial of nicotinamide for skin‐cancer chemoprevention publication-title: N Engl J Med – volume: 141 start-page: 456 year: 2005 end-page: 464 article-title: Low‐dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16‐year retrospective study publication-title: Arch Dermatol – volume: 67 start-page: 531 year: 2012 end-page: 550 article-title: AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery publication-title: J Am Acad Dermatol – volume: 367 start-page: 329 year: 2012 end-page: 339 article-title: Sirolimus and secondary skin‐cancer prevention in kidney transplantation publication-title: N Engl J Med – volume: 53 start-page: 1067 year: 2005 end-page: 1071 article-title: Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia publication-title: J Am Acad Dermatol – volume: 1 start-page: S16 year: 2015 end-page: S18 article-title: Capecitabine for squamous cell carcinoma reduction in solid organ transplant recipients publication-title: J Am Acad Dermatol Case Rep – ident: e_1_2_9_25_1 doi: 10.1111/dsu.12049 – ident: e_1_2_9_20_1 doi: 10.1200/JCO.2012.45.6376 – ident: e_1_2_9_7_1 doi: 10.1056/NEJMc1509268 – ident: e_1_2_9_9_1 doi: 10.1016/j.jaad.2012.06.009 – ident: e_1_2_9_6_1 doi: 10.1001/jamadermatol.2018.4219 – ident: e_1_2_9_23_1 doi: 10.1016/j.jaad.2017.08.058 – ident: e_1_2_9_26_1 doi: 10.1056/NEJMoa1506197 – ident: e_1_2_9_8_1 doi: 10.1016/j.ctrv.2017.12.004 – ident: e_1_2_9_10_1 doi: 10.1016/j.jaad.2015.02.1131 – ident: e_1_2_9_21_1 doi: 10.1200/JCO.2017.76.6691 – ident: e_1_2_9_32_1 doi: 10.1097/TP.0000000000001644 – ident: e_1_2_9_15_1 doi: 10.3390/jcm4061229 – ident: e_1_2_9_11_1 doi: 10.1001/jamadermatol.2016.0192 – ident: e_1_2_9_17_1 doi: 10.1007/s11864-012-0195-3 – ident: e_1_2_9_18_1 doi: 10.1126/science.1114233 – ident: e_1_2_9_28_1 doi: 10.1111/ajt.14238 – ident: e_1_2_9_30_1 doi: 10.1111/ajt.15071 – ident: e_1_2_9_14_1 doi: 10.1097/01.MLG.0000158349.64337.ED – ident: e_1_2_9_2_1 doi: 10.1001/archderm.139.3.301 – ident: e_1_2_9_27_1 doi: 10.1111/bjd.14662 – ident: e_1_2_9_22_1 doi: 10.1001/archderm.141.4.456 – ident: e_1_2_9_5_1 doi: 10.1002/cncr.30601 – ident: e_1_2_9_16_1 doi: 10.1016/j.jaad.2010.11.063 – ident: e_1_2_9_29_1 doi: 10.1016/j.healun.2007.09.019 – ident: e_1_2_9_13_1 doi: 10.1111/j.1524-4725.2007.34040.x – volume: 1 start-page: S16 year: 2015 ident: e_1_2_9_24_1 article-title: Capecitabine for squamous cell carcinoma reduction in solid organ transplant recipients publication-title: J Am Acad Dermatol Case Rep contributor: fullname: Breithaupt AD – ident: e_1_2_9_4_1 doi: 10.1001/jamadermatol.2015.4994 – ident: e_1_2_9_3_1 doi: 10.1016/j.jaad.2005.08.055 – ident: e_1_2_9_31_1 doi: 10.1634/theoncologist.2018-0195 – ident: e_1_2_9_12_1 doi: 10.1097/DSS.0000000000001645 – ident: e_1_2_9_19_1 doi: 10.1056/NEJMoa1204166 |
SSID | ssj0001158 |
Score | 2.3804483 |
SecondaryResourceType | review_article |
Snippet | Immunosuppression, both iatrogenic and disease‐related, is associated with a greatly increased incidence of cutaneous SCC (cSCC) and with aggressive cSCC and... Immunosuppression, both iatrogenic and disease-related, is associated with a greatly increased incidence of cutaneous SCC (cSCC) and with aggressive cSCC and... Abstract Immunosuppression, both iatrogenic and disease‐related, is associated with a greatly increased incidence of cutaneous SCC ( cSCC ) and with aggressive... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 57 |
Title | Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjdv.15843 https://www.ncbi.nlm.nih.gov/pubmed/31833603 https://search.proquest.com/docview/2334698537 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwED5VHRAL70d5ySAGllQmjp1GTAioqkplQAV1QIpsx5EqRFpI04Ffj89JyktIiC1DbOVyvrvvzufPAKeU-4ZGaeJJ1eFeYBMAL5I09LjQNA2ptiEY65CDW9G7D_ojPmrARX0WpuSHWBTc0DKcv0YDlyr_bOTJvH1uwycyfSKRHgKiuw_qKIt0nBeOfOEhp1bFKuS6eOqRX2PRD4D5Fa-6gNNdhcf6U8s-k6d2MVNt_faNxfGfsqzBSgVEyWW5ctahYbINWBpUW-2bIId1CzqpecdNTsYZGeOJkkleTF0LrUlIRc2aE6zpkrqpgOjC4k4zKXKSvxQSKwwEdwmIxtuLssmz3IL77s3wqudV9zF4mgnKPMG0jW1aB4IFyhileIjosiO435EhnrI1EaNJEjFhBximwzClSUekYSR1ah3ZNjSzSWZ2gQTM2NyHpyrgOkiolsK3KX6kfa4sApGsBSe1ZuJpSbsRL9KVZB67n9WC41pnsTUKlKGUK_YZw5sxOQtbsFMqczENOjEUpwVnTiW_zx_3rx_cw97fX92HZQuporLh5QCas9fCHFrYMlNHbn2-A9xm6Lg |
link.rule.ids | 315,786,790,1382,27955,27956,46327,46751 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDLYGSMCF92M8A-LApVNomnSVuCAGGo9xQBvigqo0TaUJ0QFdOfDridN2MBAS4tZDE9V1bH92nC8AB5S7mgZJ7MioyR3PJABOIKnvcKFo4lNlQjDWITs3ot3zLu_5fQ2Oq7MwBT_EqOCGlmH9NRo4FqS_Wnn81jgy8ZNNwJQxd45m2br9JI8yWMf64cAVDrJqlbxCto-nGjoejX5AzHHEakPO-Tw8VB9bdJo8NvJh1FDv33gc_yvNAsyVWJScFItnEWo6XYLpTrnbvgyyW3Whk4p6XGekn5I-HioZZPmz7aLVMSnZWTOCZV1S9RUQlRvoqQd5RrKXXGKRgeBGAVF4gVE6eJIr0Ds_6562nfJKBkcxQZkjmDLhTSlPMC_SOoq4jwCzKbjblD4etNUBo3EcMGEGaKZ8P6FxUyR-IFVifNkqTKaDVK8D8Zg26Q9PIo8rL6ZKCtdk-YFyeWRAiGR12K9UEz4XzBvhKGOJ30L7s-qwVyktNHaBMhRyhS5jeDkmZ34d1gptjqZBP4bi1OHQ6uT3-cPL1p192Pj7q7sw0-52rsPri5urTZg1CCso-l-2YHL4muttg2KG0Y5drB9ySezY |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB50BfHi-7E-o3jw0iU2TdriSVwXXR-IqHgQSpqksIjtard78NebpO3qKoJ466ENnUxm5pvJ5AvAPqauwmEiHR4H1PF0AuCEHPsOZQInPhY6BJs65NU1O7v3uo_0cQKO6rMwJT_EqOBmLMP6a2PgfZl8NXI5bB3q8EkmYcpjxDWZV_v2kztKQx3rhkOXOYZUq6IVsm089afjwegHwhwHrDbidObgqf7XstHkuVUM4pZ4_0bj-E9h5mG2QqLouFw6CzCh0kWYvqr22peA39U96KgmHlc56qWoZ46UZHnRtz20SqKKmzVHpqiL6q4CJAoNPFVW5Ch_LbgpMSCzTYCEub4ozV74Mtx3Tu9OzpzqQgZHEIaJw4jQwU0IPd1erFQcU9_Ay4BRN-C-OWarQoKlDAnTHygifD_BMmCJH3KRaE-2Ao00S9UaII8onfzQJPao8CQWnLk6xw-FS2MNQThpwl6tmahf8m5Eo3xFDiM7WU3YrXUWaaswMpRyRS4h5mpMSvwmrJbKHA1jvJgRpwkHViW_jx912w_2Yf3vr-7A9E27E12eX19swIyGV2HZ_LIJjcFbobY0hBnE23apfgDD1euH |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+approaches+in+immunosuppressed+patients+with+advanced+cutaneous+squamous+cell+carcinoma&rft.jtitle=Journal+of+the+European+Academy+of+Dermatology+and+Venereology&rft.au=Willenbrink%2C+T+J&rft.au=Jambusaria-Pahlajani%2C+A&rft.au=Arron%2C+S&rft.au=Seckin%2C+D&rft.date=2019-12-01&rft.eissn=1468-3083&rft.volume=33+Suppl+8&rft.spage=57&rft_id=info:doi/10.1111%2Fjdv.15843&rft_id=info%3Apmid%2F31833603&rft.externalDocID=31833603 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0926-9959&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0926-9959&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0926-9959&client=summon |